1. Introduction {#sec1-cancers-12-01773}
===============

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults in the Western World. Patients with CLL show heterogeneous outcomes ranging from an indolent to an aggressive clinical course \[[@B1-cancers-12-01773]\]. Approximately 2--10% of CLL patients develop additional genetic lesions leading to an increased risk of Richter Syndrome (RS), an aggressive lymphoma characterized by a high proliferative pattern \[[@B2-cancers-12-01773],[@B3-cancers-12-01773],[@B4-cancers-12-01773]\]. Several studies have demonstrated the important role of positron emission tomography/computed tomography (PET/CT) in detecting RS \[[@B5-cancers-12-01773],[@B6-cancers-12-01773],[@B7-cancers-12-01773],[@B8-cancers-12-01773],[@B9-cancers-12-01773]\]. This technique can distinguish tissues with a low 1*8F*-*fluorodeoxyglucose* (*18F*-*FDG*) uptake, such as CLL, from those with a higher metabolic pathway, such as aggressive lymphomas and second malignancies \[[@B10-cancers-12-01773],[@B11-cancers-12-01773],[@B12-cancers-12-01773],[@B13-cancers-12-01773],[@B14-cancers-12-01773],[@B15-cancers-12-01773]\]. Higher standardized uptake volume (SUV~max~) values ≥5 or ≥10, revealed a high sensitivity and specificity in detecting RS in patients treated with chemoimmunotherapy \[[@B5-cancers-12-01773],[@B6-cancers-12-01773],[@B7-cancers-12-01773],[@B8-cancers-12-01773],[@B9-cancers-12-01773]\]. On this basis, PET/CT has been considered a useful tool to identify both the presence of high metabolic disease and the optimal site for a diagnostic biopsy \[[@B5-cancers-12-01773],[@B6-cancers-12-01773],[@B7-cancers-12-01773],[@B8-cancers-12-01773],[@B9-cancers-12-01773],[@B16-cancers-12-01773]\]. However, PET cannot replace histology in the diagnostic assessment of tissues with a high 18F-FDG uptake.

In different studies, high SUV~max~ values have also been associated with poorer outcomes \[[@B6-cancers-12-01773],[@B7-cancers-12-01773],[@B17-cancers-12-01773],[@B18-cancers-12-01773]\]. In a retrospective study by Falchi et al. that included 764 CLL patients who underwent PET/CT in the susceptibility of a more aggressive disease or as clinical staging before different treatment lines, 332 (43%) patients underwent the biopsy of the involved lymph node or other tissue \[[@B6-cancers-12-01773]\]. RS was diagnosed in 95 (28.6%) patients while CLL was confirmed histologically in 237 (71.4%). In this study, the SUV~max~ values ≥ 10 identified patients with RS and were associated with inferior survival. Moreover, the patients with confirmed CLL who showed histologic features of a more aggressive disease, showed higher median SUV~max~ values, 6.8, than those of the patients with a histologic indolent disease, 3.7. Similarly, in the study by Michallet et al. SUV~max~ values ≥ 10 identified patients with RS and were associated with significantly lower survival. In this study, patients with aggressive CLL showed higher median SUV~max~ values, 4.5, compared to those with a stable disease, 2.5 \[[@B9-cancers-12-01773]\]. A prior study of our group included 90 patients in different treatment lines, who underwent PET/CT followed by a biopsy of the involved lymph nodes or other tissues in the suspicion of RS or a secondary malignancy \[[@B8-cancers-12-01773]\]. Median SUV~max~ values were 14.6 in patients with diffuse large B-cell lymphoma, 7 in those with Hodgkin lymphoma, and 3.5 in patients with the diagnosis of CLL/small lymphocytic lymphoma. In this study, ten patients with previously untreated CLL and SUV~max~ cutoff ≥5 showed a significant inferior survival probability than those with lower SUV~max~ values. This finding might suggest an unfavorable outcome of CLL patients with a more marked proliferative behavior measured by PET/CT.

While the role of PET/CT in identifying the presence of RS is well established, its prognostic role in defining the outcome of patients with a biopsy-proven CLL has been less explored. In particular, the clinical significance of PET/CT as a prognosticator has not been sufficiently investigated in patients requiring front-line chemoimmunotherapy.

To define whether PET/CT may have prognostic significance in CLL, we retrospectively analyzed the clinical characteristics and outcome of 40 patients with a biopsy-proven CLL who required front-line chemoimmunotherapy.

2. Results {#sec2-cancers-12-01773}
==========

2.1. Patient Characteristics {#sec2dot1-cancers-12-01773}
----------------------------

The clinical and biological characteristics of patients are described in [Table 1](#cancers-12-01773-t001){ref-type="table"}. The median time from PET/CT scan to biopsy was 26 days (range 14--42) and the median follow-up of patients from biopsy, 66 months (2--106). The median age at biopsy was 62 years (range 35--92). Unmutated immunoglobulin heavy chain variable region genes IGHVstatus was present in 54% of patients, and deletion 11q in 19%. The presence of a *TP*53 disruption was observed in 7/37 tested patients (19%). The fluorescent in situ hybridization FISH analysis revealed deletion 17p in 3/31 analyzed patients while *TP*53 mutation was detected in 6/37 tested patients (two patients with deletion 17p also had *TP*53 mutation). FCR (fludarabine, cyclophosphamide, rituximab) was given in 20 patients, and BR (bendamustine, rituximab) in 20.

2.2. PET/CT and Biopsy {#sec2dot2-cancers-12-01773}
----------------------

The median SUV~max~ value recorded by PET was 3.5 (range, 2.1--9), with values ≥ 5 in 13 (33%) patients and \<5 in 27 (67%). The biopsy site fully matched with that of the highest SUV~max~ value in 32 (80%) patients. In eight (20%) patients with the highest uptake projected on abdominal nodes, the biopsy targeted the largest lymph node easier to access.

2.3. Distribution of Clinical and Biologic Characteristics According to the SUV~max~ Value {#sec2dot3-cancers-12-01773}
------------------------------------------------------------------------------------------

In univariate analysis, SUV~max~ values ≥ 5 were observed more frequently in patients with biopsies characterized by a rate of Ki67 positive cells ≥ 30% (*p* = 0.02) and in those with deletion 11q (*p* = 0.006), while no significant differences in the SUV~max~ values were detected for other genetic lesions ([Table 1](#cancers-12-01773-t001){ref-type="table"}).

2.4. Outcomes of Patients According to the SUV~max~ Values {#sec2dot4-cancers-12-01773}
----------------------------------------------------------

Response to frontline therapy was observed in most patients \[overall response rate (ORR), 36/40, 90%\]. No significant differences in the overall response (OR) and complete response (CR) rates were associated with the SUV~max~ values recorded at baseline (SUV~max~ values \< 5 vs. ≥5: ORR, 93% vs. 85%; *p* = 0.43; CR, 44% vs. 46%; *p* = 0.93; [Table S1](#app1-cancers-12-01773){ref-type="app"}). After a median time of 34 months (range, 10--74 months) from the biopsy, 17 (49%) patients developed CLL progression. No statistical differences according to the SUV~max~ levels were observed in the rate of patients who developed CLL progression (SUV~max~ value ≥ 5 or \<5: CLL progression, 33% vs. 54%; *p* = 0.28; [Table S1](#app1-cancers-12-01773){ref-type="app"}) or not.

Five (13%) patients developed RS after a median time of 15 months (range, 12--32 months) from the biopsy. A significantly higher proportion of patients with SUV~max~ values ≥ 5 than those with SUV~max~ \< 5 developed RS (SUV~max~ values ≥ 5 vs. \<5; Richter Syndrome, 31% vs. 4%; *p* = 0.015; [Table S1](#app1-cancers-12-01773){ref-type="app"}). The majority of patients who developed RS showed at baseline histologic features suggesting a high proportion of proliferating cells in lymph nodes (Ki67 ≥ 30%,4/5 patients; large and confluent proliferation centers (PCs), 3/5 patients).

2.5. Survival {#sec2dot5-cancers-12-01773}
-------------

The median and 3-year progression-free survival (PFS) were 48 months and 75%, respectively. In the univariate analysis, the SUV~max~ values showed no impact on PFS (3-year PFS, SUV~max~ \< 5 vs. ≥ 5, 79 vs. 55%, *p* = 0.48; [Table 2](#cancers-12-01773-t002){ref-type="table"}). The factors with a significant impact on PFS were deletion 11q (*p* = 0.01; hazard ratio (HR) 4.21 (95% CI: 1.3--13)), biopsies with the presence of large and confluent PCs (*p* = 0.003; HR 4.5 (95% CI: 1.6--12.1)) and ≥30% of Ki67 positive cells (*p* = 0.04; HR 2.41 (95% CI: 1--5.6)). A trend for statistical significance was observed for the IGHV mutational status (*p* = 0.07), while the presence of *TP*53 aberrations showed no significant impact on PFS (*p* = 0.7). However, in multivariate analysis, the presence of deletion 11q (HR 0.28 (95% CI: 0.08--0.99)) and large and confluent PCs in the lymph-node biopsies (HR 0.17 (95% CI: 0.03--0.94)) were the only factors that maintained significance ([Figure 1](#cancers-12-01773-f001){ref-type="fig"}; [Table 2](#cancers-12-01773-t002){ref-type="table"}; [Table S2](#app1-cancers-12-01773){ref-type="app"}).

Eleven (27%) patients died, 3/27 (11%) with SUV~max~ values \< 5 and 8/13 (61%) with SUV~max~ values ≥ 5. The causes of death were disease progression in three cases, RS in four, cancer in two, cardiovascular in one, and a traumatic event in one. Median survival probability was not reached in patients with SUV~max~ values \< 5 while it was significantly lower, 56 months, in those with SUV~max~ value ≥ 5 (*p* = 0.002; HR 0.12 (95% CI:0.3--0.5)) ([Figure 2](#cancers-12-01773-f002){ref-type="fig"}, [Table 2](#cancers-12-01773-t002){ref-type="table"}).

A significantly inferior survival was also observed in the IGHV unmutated patients (*p* = 0.04; HR 0.20 (95% CI: 0.04--0.9)), in those with deletion 11q (*p* = 0.01; HR 5.49 (95% CI: 1.4--20.8)), with biopsies showing ≥ 30% of Ki67 positive cells (*p* = 0.009; HR 8.1 (95% CI: 1.7--38.6)), large and confluent PCs (*p* = 0.02; HR 5.17 (95% CI: 1.2--21.1)) ([Figure 2](#cancers-12-01773-f002){ref-type="fig"}, [Table 2](#cancers-12-01773-t002){ref-type="table"}).

However, in the multivariate analysis, two factors maintained a significant adverse impact on OS, SUV~max~ values ≥ 5 (HR 6.48 (95% CI: 1.42--29.58)) and the presence of large and confluent PCs in the lymph nodes biopsies (HR 0.14 (95% CI: 0.02--0.7)) ([Table S2](#app1-cancers-12-01773){ref-type="app"}).

The clinical, biologic characteristics of two representative cases with different outcomes and SUV~max~ values are described in the [Figure S1](#app1-cancers-12-01773){ref-type="app"}.

3. Discussion {#sec3-cancers-12-01773}
=============

PET/CT is widely used in the clinical management of CLL patients with disease progression and clinical suspicion of RS. This study was aimed at evaluating whether the SUV~max~ value could also have a prognostic impact on the outcome of patients with biopsy-proven CLL. The strength of this study was based on the homogeneity of the clinical characteristics of patients, which all showed progressive disease and performed PET/CT and the excisional biopsy of the involved lymph node or of another involved tissue before frontline therapy. The weaknesses of this study are the retrospective design, the relatively small sample size of patients, and the lack of a centralized review of biopsies and the PET/CT scans.

Clinical and histopathological signs suggesting a pronounced cell proliferation in lymph-nodes, such as large lymph-nodes, increased levels of lactate dehydrogenase (LDH), a high rate of Ki67 positive cells, and deletion 11q, were significantly more frequent in the presence of SUV~max~ values ≥ 5. The majority of patients achieved a response to front line therapy and the 18F-FDG uptake did not identify cases with a different response rate. Interestingly, in multivariate analysis, the presence of large and confluent PCs emerged as the only factor with a negative effect on both, PFS and OS. Deletion 11q, a genetic aberration frequently observed in cases with extensive lymphadenopathy \[[@B19-cancers-12-01773]\], also revealed a significant and independent impact on PFS. SUV~max~ values ≥ 5 were associated with a significantly adverse impact on OS. Median survival was not reached in the patients with SUV~max~ values \< 5, while it was significantly lower, 56 months, in those with SUV~max~ value ≥ 5. A close relationship between a high 18F-FDG uptake and inferior survival has been previously reported in other studies \[[@B6-cancers-12-01773],[@B8-cancers-12-01773],[@B9-cancers-12-01773]\].

As these studies included treatment naïve as well as previously treated patients, and were mainly focused on the discriminatory power of PET/CT in identifying cases with RS, our data are not easily comparable \[[@B5-cancers-12-01773],[@B6-cancers-12-01773],[@B7-cancers-12-01773],[@B8-cancers-12-01773],[@B9-cancers-12-01773],[@B20-cancers-12-01773],[@B21-cancers-12-01773]\]. In our study, we only considered patients with a biopsy-proven CLL performed before frontline therapy and excluded patients with RS. Given these characteristics, it is not surprising that in our study no patients showed SUV~max~ values ≥ 10. Nevertheless, our data, focused on patients with a less advanced disease, confirm the adverse impact of higher 18F-FDG uptake on survival. In a study by Mato et al. that included venetoclax-treated patients, increased SUV~max~ values were also associated with a trend to a significantly inferior survival \[[@B20-cancers-12-01773]\]. As targeted therapy is progressively replacing chemotherapy, this question deserves to be further investigated in patients treated with B-cell receptor (BCR) and BCL2 antagonists. It might be possible that the 18F-FDG uptake loses its prognostic significance on survival when it will be tested in patients treated with BCR inhibitors that have a high efficacy on the lymph node disease.

Overall, our results suggest a close relationship between a high 18F-FDG uptake, histologic features of increased cell proliferation in lymph nodes, and survival probability. In a study by Ginè et al., patients whose biopsy displayed expanded PCs showed a low survival and were defined as having an 'accelerated' CLL \[[@B18-cancers-12-01773]\]. Similarly, in a study by Falchi et al., patients with large and confluent PCs and high rates of Ki67 positive cells were classified as having a "histologically aggressive CLL" (HAC) \[[@B6-cancers-12-01773]\]. Patients with a HAC revealed higher median SUV~max~ values and inferior survival than those without HAC features \[[@B6-cancers-12-01773],[@B9-cancers-12-01773]\]. It is noteworthy that in our study, more than a third of the patients could be considered as patients with HAC at the time of the first treatment. An intriguing finding of the present study was the significantly higher rate of patients displaying SUV~max~ values ≥ 5 at baseline who developed a diffuse large B-cell lymphoma. Moreover, the majority of patients who developed RS also showed biopsies characterized by large and confluent PCs and high rates of Ki67 positive cells. This observation suggests that a pronounced cell proliferation in the lymph-node compartment could represent a risk factor for the expansion of an aggressive cell clone leading to the emergence of RS. This hypothesis has been supported by the high rate of genetic abnormalities that have been described in PCs \[[@B17-cancers-12-01773],[@B22-cancers-12-01773]\].

Taken together, PET/CT is a useful exam providing an immediate representation of both the extent of the disease burden and the proliferating activity in the lymph node compartment, which is the preferential site of activation, and the proliferation of CLL cells \[[@B23-cancers-12-01773]\]. Based on these properties, PET/CT is useful, not only in identifying patients with RS, but also CLL patients displaying a high rate of proliferating cells in the lymph node compartment and inferior survival.

4. Methods {#sec4-cancers-12-01773}
==========

4.1. Patients Population {#sec4dot1-cancers-12-01773}
------------------------

Between January 2009 and January 2019, clinical, biologic, and radiologic data of CLL patients who performed PET/CT followed by the biopsy involved lymph nodes or different tissues were collected and retrospectively analyzed.

Inclusion criteria included: (1) the diagnosis of B-cell CLL, according to the international workshop on CLL (iwCLL) criteria \[[@B19-cancers-12-01773]\]; (2) no prior treatment; (3) clinical and laboratory signs suggesting progressive disease requiring frontline therapy (bulky nodes, a rapid increase in the lymph-nodes size, extra-nodal involvement, B symptoms, increased LDH, progressive cytopenia) according to the iwCLL criteria \[[@B24-cancers-12-01773]\]; (4) PET/CT followed by a biopsy of the involved lymph node or other tissue with the highest SUV~max~; (5) histologic diagnosis of CLL/small lymphocytic lymphoma; (6) signed informed consent from the patients permitting the collection of clinical data from medical records. Exclusion criteria included: (1) histologic transformation from CLL to an aggressive lymphoma (Richter transformation); (2) histologic diagnosis of second malignancy.

Response to treatment was assessed according to the iwCLL criteria \[[@B24-cancers-12-01773]\]. The highest SUV~max~ value measured by PET provided the optimal site to perform the biopsy. In patients who showed the highest SUV~max~ projected on abdominal nodes, the largest and most easily reachable lymph node was biopsied. Forty patients with a biopsy showing a CLL/small lymphocytic lymphoma diagnosis were included in this study, while five patients, three with a RS, two with a second malignancy, were excluded ([Figure S2](#app1-cancers-12-01773){ref-type="app"}).

The following data were analyzed: demographics (sex, age), disease stage, lymph-nodes size, complete blood count with differential, beta2-microglobulin, LDH, CD38 expression, IGHV mutation status, FISH cytogenetic profile (del 13q, del 11q, del 17p, +12), *TP*53 mutations. SUV~max~ values and histologic characteristics of the biopsied tissue were also considered. Other analyzed parameters included the type of treatment, response to treatment, disease progression, death, and causes of death.

4.2. PET/CT Imaging {#sec4dot2-cancers-12-01773}
-------------------

PET/CT was performed by qualified radionuclide radiologists of nuclear medicine departments. Briefly, after at least eight-hour fasting, the patients were administered 4.0 ± 0.5 MBq/kg 18F-FDG and underwent the PET/CT scan (Discovery 710, General Electric, Milwakee, WI, USA) 60 ± 10 min later. Three-dimensional emission scans of 2.5 min per bed position were acquired from vertex to pelvis. Blood glucose levels were measured in all patients and 140 mg/dl was considered the upper limit for the 18F-FDG PET scan. Unenhanced low-dose CT (80--120 mAs using dose modulation, 80 kV, pitch of 0.938, and slice thickness of 3.75 mm) for segmented attenuation correction was carried out in each patient. Immediately after, the PET scans were acquired covering the same field of view as the CT. Images (256 × 256 matrix) were obtained with a 3D iterative ordered-subset expectation maximization (OSEM) and time of flight (TOF) technologies (GE VUE Point FX, GE Healthcare, Chicago, IL, USA). The algorithms were applied to the ratio sinograms using attenuation-weighted iterative reconstruction (three iterations, 18 subsets) and all the reconstructions always included a *z* axis filter. Ten millimeter-long circular region of interest (ROI) including 58 pixels was used to extract the standardized uptake value based on the body weight (SUVbw) values in a region with increased 18F-FDG uptake ([Figure S3](#app1-cancers-12-01773){ref-type="app"}). A pathologic lesion with increased 18FDG uptake was defined as a pathologic area shown by TC with an increased uptake that appeared focal, and more intense than that of the adjacent background tissues.

The SUV~max~ values of involved lymph nodes or other involved tissues were recorded. Based on the results of our prior study \[[@B8-cancers-12-01773]\], the patients' characteristics and outcomes were analyzed according to a SUVmax cut-off of five or higher.

4.3. Histologic Analysis {#sec4dot3-cancers-12-01773}
------------------------

An excisional lymph node biopsy was performed in all cases. The site with the highest SUV was considered to drive the biopsy to the most metabolically active area within a lymph node or to extra nodal tissue. Experienced pathologists of local academic institutions evaluated the histologic specimens. All the cases diagnosed as CLL/small lymphocytic lymphoma (SLL) were included in this study. The PCs were defined as described previously \[[@B18-cancers-12-01773]\]. PCs with the major diameter exceeding the ax20 microscopic field were considered as large. Ki-67 index was evaluated by immunostaining (Dako, Glostrup, Denmark) in 8--10 PCs, as described previously \[[@B18-cancers-12-01773]\]. A Zeiss Axiophot microscope (Carl Zeiss, Sheung kehen, Germany) was used.

4.4. Statistical Analysis {#sec4dot4-cancers-12-01773}
-------------------------

Patients' characteristics were reported using the median for continuous variables and frequency for categorical variables. A chi-square test was used to assess the association between the categorical variables and the patients' characteristics. Overall survival (OS) was calculated from the time of biopsy until death or last follow-up, progression-free survival (PFS) was calculated from the time of biopsy until disease progression, death, or last follow-up. The Kaplan--Meier method was considered to estimate the survival probabilities and differences between the survival curves assessed using the log-rank test. Univariate and multivariate Cox regression analyses were performed to evaluate the association between the patients' characteristics and survival.

Statistical significance was considered for *p* values ≤ 0.05. All the calculations were made using a standard statistical package (SPSS for Windows Version 25.0; Chicago, IL, USA).

4.5. Ethics {#sec4dot5-cancers-12-01773}
-----------

This retrospective, observational study was carried out according to the Guidelines for Good Clinical Practice and was approved by the Ethics Committee (Rif.3342/11.09/2014). Patients were asked to provide informed consent.

5. Conclusions {#sec5-cancers-12-01773}
==============

Our results show that higher SUV~max~ values identify CLL patients with a pronounced rate of proliferating cells in the lymph-node compartment, inferior survival, and an increased risk of developing RS. The prognostic significance of PET/CT deserves to be further investigated in trials, including the CLL patients treated with novel agents.

###### 

Click here for additional data file.

The following are available online at <https://www.mdpi.com/2072-6694/12/7/1773/s1>, Figure S1: Two representative cases with different SUV~max~ values, Figure S2: Consort diagram-trial profile, Figure S3: Example of ROI positioning, Table S1: Response to treatment, CLL progression, Richter syndrome according to the SUV~max~ values, Table S2: Multivariable Cox regression model for PFS and OS.
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![Progression-free survival (PFS) of patients with biopsy-proven CLL. (**A**) Thirty-six-month PFS according to the characteristics of proliferation centers (PCs): patients without large and confluent PCs, 85% (95% CI: 71.4--98.6) vs. with large and confluent PCs, 30% (95% CI: 12--78); *p* = 0.003. (**B**) Thirty-six-month PFS according to Ki67% expression: patients with Ki67% \< 30, 85% (95% CI: 70--100) vs. patients with Ki67% ≥ 30, 51% (95% CI: 25.3--77.3); *p* = 0.04. (**C**) Thirty-six-month PFS according to deletion (11q): patients without del(11q), 75% (95% CI: 77.6--92.4) vs. patients with del(11q), 40% (95% CI: −1--81); *p* = 0.01.](cancers-12-01773-g001){#cancers-12-01773-f001}

![Overall survival (OS) of patients with biopsy-proven CLL. (**A**) Thirty-six-month OS according to the SUV~max~ \< 5, 100% vs. SUV~max~ ≥ 5, 83% (95% CI: 64--102); *p* = 0.002. (**B**) Thirty-six-month OS according to the characteristics of proliferation centers (PCs): patients without large and confluent PCs, 96% (95% CI: 88.5--103.5) vs. with large and confluent PCs, 85% (95% CI: 89.3--110); *p* = 0.02. (**C**) Thirty-six-month OS according to Ki67% expression: Ki67% \< 30, 100% vs. Ki67% ≥ 30, 93% (95% CI: 80.4--105.6); *p* = 0.009. (**D**) Thirty-six-month OS according to IGHV mutational status: IGHV mutated, 100% vs. IGHV unmutated, 90% (95% CI: 76.7--103.2), *p* = 0.04 (**E**) Thirty-six-month OS according to deletion (11q): patients without del(11q), 100% vs. patients with del(11q), 83% (95% CI: 53--113); *p* = 0.01.](cancers-12-01773-g002){#cancers-12-01773-f002}

cancers-12-01773-t001_Table 1

###### 

Clinical and biologic characteristics of the patients with biopsy-proven chronic lymphocytic leukemia (CLL) according to the SUV~max~ values.

  -------------------------------------------------------------------------------------------------
  Tested Variables                     All Patients\   SUV~max~ ≥ 5\   SUV~max~ \< 5\   *p* Value
                                       *n* (%)         *n* (%)         *n* (%)          
  ------------------------------------ --------------- --------------- ---------------- -----------
                                       40 (100)        13 (33)         27 (67)          \-

  Age                                                                                   

  ≥65 years                            14 (35)         6 (46)          8 (30)           0.30

  \<65 years                           26 (65)         7 (54)          19 (70)          

  Sex                                                                                   

  Male                                 31 (78)         12 (92)         19 (70)          0.12

  Female                               9 (22)          1(8)            8 (30)           

  Binet stage                                                                           

  A+B                                  34 (85)         11 (85)         23 (85)          0.96

  C                                    6 (15)          4 (15)          2 (15)           

  B symptoms                                                                            

  Present                              11 (28)         3 (23)          8 (30)           0.66

  Absent                               29 (72)         10 (77)         19 (70)          

  LDH                                                                                   

  Normal                               13 (33)         6 (50)          20 (74)          0.14

  Increased                            26 (67)         6 (50)          7 (26)           

  Beta 2 microglobulin                                                                  

  ≥3.5 mg/L                            21 (58)         4 (40)          11 (42)          0.9

  \<3.5 mg/L                           15 (42)         6 (60)          15 (58)          

  Lymph nodes diameter                                                                  

  ≥5 cm                                17 (46)         8 (62)          9 (38)           0.16

  \<5 cm                               20 (54)         5 (38)          15 (62)          

  Large and confluent PCs                                                               

  Present                              9 (24)          4 (36)          5 (19)           0.26

  Absent                               28 (76)         7 (64)          21 (81)          

  Ki67%                                                                                 

  ≥30%                                 15 (40)         8 (67)          7 (27)           0.02

  \<30%                                23 (60)         4 (33)          19 (73)          

  CD38 positive                                                                         

  Present                              18 (47)         7 (58)          11 (44)          0.41

  Absent                               19 (51)         5 (42)          14 (56)          

  Unmutated IGHV                                                                        

  Present                              21 (54)         9 (75)          12 (44)          0.07

  Absent                               18 (46)         3 (25)          15 (56)          

  FISH ^b^                                                                              

  Del(11q)                                                                              

  Present                              6 (19)          5 (45)          1 (5)            0.006

  Absent                               25 (81)         6 (55)          19 (95)          

  Trisomy 12                                                                            

  Present                              8 (26)          4 (36)          4 (20)           0.32

  Absent                               23 (74)         7 (64)          16 (80)          

  Del(13q)                                                                              

  Present                              5 (16)          1 (9)           4 (20)           0.43

  Absent                               26 (84)         10 (91)         16 (80)          

  Del(17p) and/or mutated *TP*53 ^c^                                                    

  Present                              7 (19)          3 (27)          4 (15)           0.39

  Absent                               30 (81)         8 (72)          22 (85)          
  -------------------------------------------------------------------------------------------------

Abbreviations: BR, bendamustine, rituximab; Del, deletion; F, female; FCR, fludarabine, cyclophosphamide, rituximab; LDH, lactate dehydrogenase; PCs, proliferation centers; SUV, Standardized uptake value; WBC, white blood cell. Extra-nodal involvement in 3 patients: skin two cases, gastric one case. ^b^ FISH investigated in 31 patients, *TP*53 mutation investigated in 37. ^c^ Deletion 17p detected in 3/31 patients. *TP*53 mutation detected in 6/37 patients (2 patients with deletion 17p also had TP53 mutation).

cancers-12-01773-t002_Table 2

###### 

PFS and OS according to the baseline characteristics of the patients: univariate analysis.

  -------------------------------------------------------------------------------------------------------------------
  Tested Variables                 No. Patients\   PFS   OS                                             
                                   *n* (%)                                                              
  -------------------------------- --------------- ----- ---- ------- ------------- ----- ----- ------- -------------
                                   40 (100)        75    48   \-      \-            94    \-    \-      \-

  SUV~max~                                                                                              

  ≥5                               13 (33)         55    37   0.48    0.72\         83    56    0.002   0.12\
                                                                      (0.2--1,7)                        (0.3--0.5)

  \<5                              27 (67)         79    49   100     \-                                

  Age                                                                                                   

  ≥65 years                        14 (35)         62    47   0.78    1.13\         84    126   0.33    1.81\
                                                                      (0.4--2.7)                        (0.5--6)

  \<65 years                       26 (65)         75    48   100     \-                                

  Sex                                                                                                   

  Male                             31 (78)         68    47   0.44    0.65\         100   \-    0.21    0.02\
                                                                      (0.2--1.9)                        (0--8.6)

  Female                           9 (22)          85    53   93      \-                                

  B symptoms                                                                                            

  Present                          11 (28)         72    47   0.57    1.28\         100   126   0.37    0.50\
                                                                      (0.5--3)                          (0.1--2.3)

  Absent                           29 (72)         71    48   92      \-                                

  Binet stage                                                                                           

  A+B                              34 (85)         71    47   0.45    0.57\         93    \-    0.65    0.62\
                                                                      (0.1--2.4)                        (0.8--4.9)

  C                                6 (15)          75    49   100     \-                                

  LDH                                                                                                   

  Normal                           13 (33)         70    62   0.31    1.56\         91    \-    0.75    0.80\
                                                                      (0.6--3.6)                        (0.2--3.1)

  Increased                        26 (67)         74    42   90      \-                                

  Beta 2 microglobulin                                                                                  

  ≥3.5 mg/L                        21(58)          77    53   0.31    6.35\         92    \-    0.94    0.95\
                                                                      (0.2--1.5)                        (0.2--3.5)

  \<3.5 mg/L                       15 (42)         64    42   95      \-                                

  Lymph nodes diameter                                                                                  

  ≥5 cm                            17 (46)         67    44   0.78    1.1\          94    \-    0.35    1.7\
                                                                      (0.4--2.6)                        (0.5--5.8)

  \<5 cm                           20 (54)         73    47   93      \-                                

  Large and confluent PCs                                                                               

  Present                          9 (24)          30    35   0.003   4.50\         85    59    0.02    5.17\
                                                                      (1.6--12.1)                       (1.2--21.1)

  Absent                           28 (76)         85    62   96      0                                 

  Ki67%                                                                                                 

  ≥30%                             15 (40)         58    40   0.04    2.41\         93    126   0.009   8.1\
                                                                      (1--5.6)                          (1.7--38.6)

  \<30%                            23 (60)         85    53   100     \-                                

  CD38+                                                                                                 

  Present                          18 (47)         65    49   0.93    0.96\         92    126   0.20    2.19\
                                                                      (0.3--2.4)                        (0.6--7.2)

  Absent                           19 (51)         73    47   89      \-                                

  Unmutated IGHV                                                                                        

  Present                          21 (54)         59    40   0.07    0.43\         95    \-    0.04    0.20\
                                                                      (0.2--1)                          (0.04--0.9)

  Absent                           18 (46)         86    53   100     \-                                

  Del(17p) and or mutated *TP*53                                                                        

  Present                          7 (19)          57    47   0.70    1.21\         83    126   0.71    1.31\
                                                                      (0.4--3.3)                        (0.3--5.6)

  Absent                           30 (81)         76    48   96      \-                                

  Del(11q)                                                                                              

  Present                          6 (19)          75    32   0.01    4.21\         83    40    0.01    5.49\
                                                                      (1.3--13)                         (1.4--20.8)

  Absent                           25 (81)         40    48   100     \-                                

  Trisomy 12                                                                                            

  Present                          8 (26)          85    49   0.43    0.64\         100   \-    0.93    0.40\
                                                                      (0--1.9)                          (0.05--3.2)

  Absent                           23 (74)         64    47   95      126                               

  Del(13q)                                                                                              

  Present                          4(14)           50    35   0.20    2.04\         100   \-    0.60    0.57\
                                                                      (0.6--6.1)                        (0.07--4.5)

  Absent                           27 (86)         72    47   95      126                               
  -------------------------------------------------------------------------------------------------------------------

Abbreviations: BR, bendamustine, rituximab; Del, deletion; FCR, fludarabine, cyclophosphamide, rituximab; HR, hazard ratio; LDH, lactate dehydrogenase; PCs, proliferation centers; OS, overall survival; PFS, progression-free survival; SUV, standardized uptake value.
